Scartec Therapeutics

Scartec's approach provides an opportunity to address advanced-stage fibrosis, a challenging condition with limited therapeutic options. Currently, we are progressing ST-101, a highly specific ITG-A5 binding peptide, targeting fibrosis in pancreatic cancer and, in the lung. Our strong scientific foundation supports potential expansion into additional indications.

For partnership opportunities or general enquires contact -